Shanghai Henlius Biotech Co. Ltd.

Elevar Therapeutics, a US subsidiary of South Korea’s HLB LifeScience, and China’s Jiangsu Hengrui Pharmaceuticals on 21 March received a complete response letter from the US Food and Drug Administrat

A little over two months into 2025 and two Chinese drug makers have reaped the successes of moving their first-in-class pipeline innovations onto the domestic market, while two others have encountered

“Either for young biotech or established pharma companies in China, a combination of innovation and globalization is the trend,” Shan Jiang, chief technology officer at Hansoh Pharmaceutical, told the

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C